Related references
Note: Only part of the references are listed.Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
Taku Kobayashi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis
Saurabh Kedia et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Trial designs using real-world data: The changing landscape of the regulatory approval process
Elodie Baumfeld Andre et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies
Sang Joon Lee et al.
BIODRUGS (2020)
Synthetic and External Controls in Clinical Trials - A Primer for Researchers
Kristian Thorlund et al.
CLINICAL EPIDEMIOLOGY (2020)
Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review
Laura Martelli et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
Byong Duk Ye et al.
LANCET (2019)
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
Brian G. Feagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Tomoo Nakagawa et al.
INTESTINAL RESEARCH (2019)
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Yukinori Sakata et al.
DRUGS-REAL WORLD OUTCOMES (2019)
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2018)
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Synthetic control methodology as a tool for evaluating population-level health interventions
Janet Bouttell et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2018)
Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making
Vaibhav B. Katkade et al.
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2018)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Hepatotoxicity Associated with the Use of Anti-TNF-α Agents
Joshua B. French et al.
DRUG SAFETY (2016)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
Mark T. Osterman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer L. Jones et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele et al.
GUT (2015)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Risk of tuberculosis with anti- tumor necrosis factor- a therapy: substantially higher number of patients at risk in Asia
Sandra V. Navarra et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2014)
Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management
Roberta Elisa Rossi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
Marwan Ghabril et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts
Akihiro Tamori et al.
JOURNAL OF GASTROENTEROLOGY (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Usefulness of a large automated health records database in pharmacoepidemiology
Hirokuni Hashikata et al.
Environmental Health and Preventive Medicine (2010)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
T. Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: Guidelines for clinical approach
Debbie M. Nathan et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2006)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
